Anti-CD19 Antibody Lyophilization for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Therapeutic antibodies like anti-CD19 antibodies face challenges in maintaining biological activity due to chemical and physical instabilities during storage, leading to short shelf lives and potential increased immune responses in patients.
Innovation Solution
Development of stable lyophilized pharmaceutical formulations comprising an anti-CD19 antibody with specific concentrations of sucrose, trehalose, or mannitol, polysorbate, and citrate or phosphate buffers at a pH of about 6.0, which help preserve the antibody's conformational integrity and prevent degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic antibodies are stored in conventional formulations, then they can be administered to patients, but they suffer from chemical and physical instabilities leading to short shelf lives and potential increased immune responses
Solution Approach 1:
The patent changes the pH parameter to about 6.0 (optimal stability range) and adjusts concentrations of excipients including sucrose (1-10% w/v), trehalose (0.1-10% w/v), mannitol (0.1-10% w/v), polysorbate (0.01-1% w/v), and buffers (10-100 mM). These parameter optimizations prevent aggregation and degradation, maintaining at least 60% biological activity after storage, thus resolving the contradiction between stability and shelf life
Solution Approach 2:
The formulation uses a composite system combining multiple excipients with specific functions: sugars (sucrose, trehalose, mannitol) as stabilizers and cryoprotectants, polysorbate as surfactant to prevent surface aggregation, and buffers (citrate or phosphate) to maintain pH. This composite formulation approach addresses both chemical and physical instabilities simultaneously, extending shelf life while maintaining reliability
2Duration of action of stationary object
If the antibody formulation is optimized for long-term storage stability, then shelf life is extended, but the formulation complexity increases with multiple excipients and specific pH control
Solution Approach 1:
The formulation employs multi-functional excipients that simultaneously address multiple stability issues. For example, sugars serve as both stabilizers preventing denaturation and cryoprotectants preventing freeze-damage; polysorbate provides both surfactant activity against aggregation and solubility enhancement; buffers maintain pH while providing ionic strength. This multi-functionality reduces the need for separate additives, managing formulation complexity while achieving extended shelf life
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations provide a stable and biologically active anti-CD19 antibody, maintaining at least 60% of its biological activity after storage, suitable for extended shelf life and reduced immune response risks.
Implementation Method 1
stable lyophilized pharmaceutical formulations comprising an anti-CD19 antibody with specific concentrations of sucrose, trehalose, or mannitol
Implementation Method 2
help preserve the antibody's conformational integrity and prevent degradation
Implementation Method 3
stable lyophilized pharmaceutical formulations comprising an anti-CD19 antibody with specific concentrations of sucrose, trehalose, or mannitol, polysorbate
Implementation Method 4
citrate or phosphate buffers at a pH of about 6.0, which help preserve the antibody's conformational integrity
Implementation Method 5
stable lyophilized pharmaceutical formulations comprising an anti-CD19 antibody
Data Source
AI summary
The present disclosure describes a pharmaceutical formulation of an anti-CD19 antibody.